Jazz Pharmaceuticals plc / EUSA Pharma

Acute Lymphoblastic Leukemia (ALL) — patients hypersensitive to E. coli-derived asparaginase

4K US cases/yr · $180M Erwinaze US peak revenue opportunity (Jefferies analyst estimate, 2012)

Disease Overview

Acute lymphoblastic leukemia is the most common pediatric cancer, with asparaginase therapy a backbone of induction and consolidation regimens because leukemic blasts cannot synthesize asparagine. Up to 30-45% of patients develop hypersensitivity reactions to E. coli-derived asparaginase, ranging from rash to anaphylaxis, and silent inactivation reduces efficacy — leaving Erwinia-derived asparaginase as the critical salvage therapy.

Competitive Landscape

The ALL asparaginase landscape in 2012 was effectively a three-product, single-class market: native E. coli L-asparaginase (Elspar, Lundbeck/Merck), pegaspargase (Oncaspar, Sigma-Tau/later Servier), and Erwinaze (asparaginase Erwinia chrysanthemi, EUSA Pharma). Pegaspargase had become the front-line workhorse with a longer half-life and reduced immunogenicity, but 3-45% of patients still developed clinical hypersensitivity, leaving Erwinaze as the only FDA-approved option for those patients to complete intended asparaginase exposure (FDA approval Nov 2011, orphan exclusivity through 2018). Pricing reflected scarcity at ~$150K per patient course, and Jefferies estimated US peak potential at ~$180M annually. For Jazz, the EUSA deal added Erwinaze, EUSA's existing US/EU specialty commercial infrastructure, and ~$210-230M of expected 2013 revenue — diversifying beyond Xyrem narcolepsy concentration risk into oncology specialty for the first time. The competitive risk was always supply: Erwinaze faced repeated manufacturing-driven shortages, and a recombinant successor (Rylaze, Jazz, approved 2021) eventually replaced it after the Erwinaze franchise was lost in 2020 due to manufacturing failure.